Suppression of phenotypes for ALS-FTD therapy discovery.

Mutations in are linked to a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). The orthologue of is and we investigated whether mutants could be used for therapeutic discovery in ALS-FTD. Our results show that the small molecule pioglitazone and the probiotic HA-114 can alleviate mutant phenotypes. These findings suggest that mutants are suitable for modifier screens and could be adapted for high-throughput drug screening and microbiome studies to aid in discovering therapies for ALS-FTD.